Base Editing: The Next Frontier in Genome Editing Technology
Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights…
Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights…
Update (14/01/20): Horizon Discovery will offer partners access to a precise version of CRISPR gene…
Biotech entrepreneur Darrin Disley, ex-CEO and co-founder of the successful Cambridge gene editing biotech Horizon…
The emergence of CRISPR/Cas9 technologies has enabled almost unlimited gene editing opportunities. Not only could…
Synthetic biology, or synbio for short, is rapidly infiltrating multiple fields. From bioplastics to food…
Access to data is still the main bottleneck for genomic researchers. Repositive has created a…
Cambridge's image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there's also an…
Horizon Discovery now has full access to CRISPR technology and will develop an automated gene…
The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish…
An American outfit from Third Rock Ventures, Fulcrum Therapeutics, has made a deal with Horizon to…
Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal?…
Horizon Discovery is a gene-editing tools specialist with various biotech partnerships over their cell-line catalogues.…